A Study of CSPCHA131 in Patients With Advanced Solid Tumor

Inclusion Criteria: * 1.18-75 years of age. * 2\. Histologically or cytologically confirmed diagnosis of advanced or metastatic malignant solid tumors, for which standard therapy either does not exist or has been proven ineffective or intolerable for the patient. * 3\. At least one measurable tumor lesion according to RECIST version 1.1. * 4\. ECOG performance status of 0 or 1. * 5\. Life expectancy ≥ 3 months. No cardiac insufficiency or serious abnormalities in the electrocardiogram at baseline. Exclusion Criteria: * 1\. Administration of chemotherapy, radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy, other anti-tumor treatments or an investigational drug within 4 weeks or 5 half-lives, whichever is longer, preceding the first dose of study treatment. * 2\. Have undergone surgery within 4 weeks prior to the study treatment or have not fully recovered from any previous invasive procedure. * 3\. Adverse reactions to previous anti-tumor treatments that levels have not recovered to grade 1 or less. * 4\. Patients with evidence of uncontrolled nervous system metastasis or meningeal metastases, in the opinion of the investigator, not suitable for enrollment. * 5\. Active infections of grade 2 or above. * 6\. Peripheral neuropathy of grade 2 or above.